Johnson & Johnson scores an FDA first with nod for twice-yearly schizophrenia drug Invega Hafyera

Johnson & Johnson thinks a longer-acting treatment against schizophrenia will help keep patients on their prescriptions and reduce their chances of a relapse. Now, with a FDA nod under its belt, the company is pushing Invega Hafyera as just the med to fit the bill.